至今,GenScript的服务及产品已被Cell, Nature, Science, PNAS等1300多家生物医药类杂志引用近万次,处于行业领先水平。NIH、哈佛、耶鲁、斯坦福、普林斯顿、杜克大学等约400家全球著名机构使用GenScript的基因合成、多肽服务、抗体服务和蛋白服务等成功地发表科研成果,再次证明GenScript 有能力帮助业内科学家Make research easy.

Efficacy of genotype-matched vaccine against re-emerging genotype V Japanese encephalitis virus

Emerg Microbes Infect. 2024-04; 
Jae-Deog Kim, Ah-Ra Lee, Dah-Hyun Moon, Young-Uk Chung, Su-Yeon Hong, Hyo Je Cho, Tae Hyun Kang, Yo Han Jang, Myung Hyun Sohn, Baik-Lin Seong, Sang-Uk Seo
Products/Services Used Details Operation
Proteins, Expression, Isolation and Analysis … Cells were harvested and lysed by sonication, followed by purification using Ni-NTA resin (Qiagen, California, USA). To remove the Cha domain, TEV protease (Genscript, NJ, USA) … Get A Quote

摘要

Japanese encephalitis (JE), caused by the Japanese encephalitis virus (JEV), is a highly threatening disease with no specific treatment. Fortunately, the development of vaccines has enabled effective defense against JE. However, re-emerging genotype V (GV) JEV poses a challenge as current vaccines are genotype III (GIII)-based and provide suboptimal protection. Given the isolation of GV JEVs from Malaysia, China, and the Republic of Korea, there is a concern about the potential for a broader outbreak. Under the hypothesis that a GV-based vaccine is necessary for effective defense against GV JEV, we developed a pentameric recombinant antigen using cholera toxin B as a scaffold and mucosal adjuvant, which was con... More

关键词

Japanese encephalitis virus, genotype V, neutralizing antibody, recombinant vaccine; bivalent vaccine